XML 54 R11.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue
 3 Months Ended
Mar. 31, 2020
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The following table summarizes our revenue recognized in our consolidated condensed statements of operations:
 
Three Months Ended
March 31,
 
2020
 
2019
Net product revenue
$
5,403.5

 
$
4,692.3

Collaboration and other revenue (1)
456.3

 
399.9

Revenue
$
5,859.8

 
$
5,092.2

(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $35.4 million and $35.5 million during the three months ended March 31, 2020 and 2019, respectively.
We recognize revenue primarily from two different types of contracts, product sales to customers (net product revenue) and collaborations and other arrangements. Revenue recognized from collaborations and other arrangements includes our share of profits from the collaboration, as well as royalties, upfront and milestone payments we receive under these types of contracts. See Note 4 for additional information related to certain of our collaborations and other arrangements. Collaboration and other revenue disclosed above includes the revenue from the Trajenta® and Jardiance® families of products resulting from our collaboration with Boehringer Ingelheim discussed in Note 4. Substantially all of the remainder of collaboration and other revenue is related to contracts accounted for as contracts with customers.
Adjustments to Revenue
Adjustments to revenue recognized as a result of changes in estimates for our most significant U.S. sales returns, rebates, and discounts liability balances for products shipped in previous periods were approximately 2 percent and 3 percent of U.S. revenue during the three months ended March 31, 2020 and 2019, respectively.
Contract Liabilities
Our contract liabilities result from arrangements where we have received payment in advance of performance under the contract and do not include sales returns, rebates, and discounts. Changes in contract liabilities are generally due to either receipt of additional advance payments or our performance under the contract.
The following table summarizes contract liability balances:
 
March 31, 2020
 
December 31, 2019
Contract liabilities
$
307.8

 
$
264.6


During the three months ended March 31, 2020 and 2019, revenue recognized from contract liabilities as of the beginning of the year was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.

Disaggregation of Revenue
The following table summarizes revenue by product:
 
Three Months Ended
March 31,
 
2020
 
2019
 
United States (U.S.) (1)
Outside U.S.
Total
 
U.S. (1)
Outside U.S.
Total
Revenue—to unaffiliated customers:
 
 
 
 
 
 
 
Diabetes:
 
 
 
 
 
 
 
Trulicity®
$
929.5

$
299.9

$
1,229.4

 
$
665.6

$
214.1

$
879.7

Humalog® (2)
398.6

297.2

695.8

 
448.6

282.2

730.8

Humulin®
214.1

101.5

315.7

 
201.3

96.4

297.7

Basaglar®
230.4

73.3

303.7

 
198.2

53.2

251.4

Jardiance (3)
144.6

122.9

267.5

 
125.2

78.4

203.6

Trajenta (4)
28.7

64.5

93.2

 
47.4

84.6

131.9

Other Diabetes
45.3

18.4

63.6

 
33.1

24.7

57.9

Total Diabetes
1,991.2

977.7

2,968.9

 
1,719.4

833.6

2,553.0

 
 
 
 
 
 
 
 
Oncology:
 
 
 
 
 
 
 
Alimta®
324.2

235.8

560.1

 
281.8

217.4

499.2

Cyramza®
89.1

149.9

239.0

 
75.1

123.2

198.3

Verzenio®
129.4

58.6

188.0

 
93.5

15.9

109.4

Erbitux®
117.8

13.0

130.8

 
113.3

5.1

118.4

Other Oncology
(2.6
)
86.3

83.6

 
30.2

57.3

87.4

Total Oncology
657.9

543.6

1,201.5

 
593.9

418.9

1,012.7

 
 
 
 
 
 
 
 
Immunology:
 
 
 
 
 
 
 
Taltz®
327.5

116.0

443.5

 
180.8

71.7

252.5

Olumiant®
11.3

128.4

139.7

 
6.4

75.7

82.1

Other Immunology
2.6

—

2.6

 
—

—

—

Total Immunology
341.4

244.4

585.8

 
187.2

147.4

334.7

 
 
 
 
 
 
 
 
Neuroscience:
 
 
 
 
 
 
 
Cymbalta®
11.6

198.8

210.4

 
10.3

153.8

164.1

Zyprexa®
11.2

87.2

98.4

 
9.3

97.9

107.2

Emgality®
67.3

6.7

74.0

 
12.2

2.1

14.2

Other Neuroscience
20.2

60.5

80.7

 
19.3

88.2

107.6

Total Neuroscience
110.3

353.2

463.5

 
51.1

342.0

393.1

 
 
 
 
 
 
 
 
Other:
 
 
 
 
 
 
 
Forteo®
122.5

149.8

272.4

 
125.9

187.0

312.9

Cialis®
26.1

167.0

193.0

 
143.2

164.9

308.2

Other
79.4

95.3

174.7

 
70.1

107.6

177.6

Total Other
228.0

412.1

640.1

 
339.2

459.5

798.7

Revenue
$
3,328.8

$
2,531.0

$
5,859.8

 
$
2,890.8

$
2,201.4

$
5,092.2

Numbers may not add due to rounding.
(1) U.S. revenue includes revenue in Puerto Rico.
(2) Humalog revenue includes Insulin Lispro.
(3) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR.
(4) Trajenta revenue includes Jentadueto®. 
.
The following table summarizes revenue by geographical area:
 
Three Months Ended
March 31,
 
2020
 
2019
Revenue—to unaffiliated customers (1):
 
 
 
U.S. (2)
$
3,328.8

 
$
2,890.8

Europe
1,061.0

 
900.3

Japan
592.3

 
543.7

China
267.3

 
211.2

Other foreign countries
610.4

 
546.2

Revenue
$
5,859.8

 
$
5,092.2

Numbers may not add due to rounding.
(1) Revenue is attributed to the countries based on the location of the customer.
(2) U.S. revenue includes revenue in Puerto Rico.